HER2/neu gene amplification and consequent over expression of HER2/neu receptor have been observed in a significant proportion of human tumours, particularly in breast cancer, and are intimately associated with malignant phenotype and aggressiveness of the malignancy4–7. Here, ERBB2 is linked to breast carcinoma.